Individualization of levodopa therapy.
D000547:Amantadine / Q000627:therapeutic use; D000661:Amphetamine / Q000627:therapeutic use; D000777:Anesthetics; D000818:Animals; D000959:Antihypertensive Agents / Q000009:adverse effects; D001058:Apomorphine / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000209:etiology; D002230:Carbidopa / Q000627:therapeutic use; D003864:Depression, Chemical; D004032:Diet; D004221:Disulfiram / Q000627:therapeutic use; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D004702:Endocrine Glands / Q000187:drug effects; D005901:Glaucoma / Q000150:complications; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007980:Levodopa / Q000008:administration & dosage* / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D051379:Mice; D010276:Parasympatholytics / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D013270:Stomach / Q000187:drug effects / Q000502:physiology
D000777:Anesthetics; D000959:Antihypertensive Agents; D010276:Parasympatholytics; D007980:Levodopa; D000547:Amantadine; D000661:Amphetamine; D002230:Carbidopa; D001058:Apomorphine; D004221:Disulfiram